Table 4.
pSTAT3 IHC staining of a patient who achieved a PR post-treatment with napabucasin
| Percent nuclear tumor staining |
% Nuclear tumor positive | H-score | Microenvironment | |||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 + | 2 + | 3 + | % positive | intensity | |||
| Baseline | 94 | 5 | 1 | 0 | 6 | 7 | 20 | 2 |
| Post-napabucasin | 90 | 5 | 5 | 0 | 10 | 15 | 50 | 2 |
| Post-TAS-102 | 98 | 2 | 0 | 0 | 2 | 2 | 30 | 2 |
Post-napabucasin: Day 26 from the first dose of napabucasin. Treatment with napabucasin was ongoing at the time of sample collection. Post-TAS-102: Day 70 from TAS-102 first administration
pSTAT3-positivity was defined as cancer cell nuclear staining of ≥ 5% plus a stroma staining score of at least 2
IHC immunohistochemistry, PR partial response, TAS-102 trifluridine and tipiracil